ReviewThe protein journal2026
Structure-Based Drug Design Targeting the Substrate-Binding Pocket of MexB.
Review in The protein journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multidrug-resistant (MDR) phenotype of Pseudomonas aeruginosa poses a significant clinical challenge and frequently causes severe and potentially lethal infections. The activity of efflux proteins, which are membrane transporters that use the electrochemical gradient across the bacterial membrane to extrude antimicrobials and reduce their intracellular concentrations, is a significant factor in this resistance. One of the most well-known mechanisms of multidrug resistance in Pseudomonas aeruginosa is the Resistance-Nodulation-Division (RND) efflux pump system. MexB, the inner membrane transporter, is essential for substrate recognition and drug binding in the well-characterised MexAB-OprM complex. A variety of antibiotics, such as Macrolides, Fluoroquinolones, Tetracyclines, Sulfonamides, β-Lactams, Trimethoprim, Novobiocin, and Chloramphenicol, are resistant to this pump. The overexpression of this tripartite efflux system, which consists of the outer membrane channel OprM, the membrane fusion protein MexA, and the inner membrane transporter MexB, is regulated by genes including mexR, nalC, and nalD. MexB involvement in drug resistance makes it a prime target for the development of efflux pump inhibitors (EPIs). Antibiotics and EPIs together have the potential to restore antibacterial activity by enhancing intracellular drug retention. However, restricted access to complex structural and computational tools required for logical drug design has hindered the development of EPI. This study examines novel EPIs that target P. aeruginosa RND-type efflux systems and discusses recent structural discoveries regarding the MexB transporter.
Indexed as
Identifiers
41708976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.